Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

How Clovis’ Rociletinib And AstraZeneca’s AZD9291 Development Programs Stack Up

Executive Summary

Clovis and AstraZeneca have kept pace regarding submissions of breakthrough EGFR inhibitors rociletinib and AZD9291, but clinical trial programs suggests the big pharma is far ahead in overall development.

Advertisement

Related Content

AstraZeneca’s Iressa, Now Resurrected, Faces Daunting U.S. EGFR Market

Topics

Related Companies

Related Deals

Advertisement
UsernamePublicRestriction

Register

PS057074

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel